The effect of adalimumab on cardiovascular and metabolic risk factors in the treatment of patients with moderate to severe psoriasis vulgaris in comparison to a standard therapy (fumaric acid) [Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherapie (Fumarsäureester)]

Trial Profile

The effect of adalimumab on cardiovascular and metabolic risk factors in the treatment of patients with moderate to severe psoriasis vulgaris in comparison to a standard therapy (fumaric acid) [Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherapie (Fumarsäureester)]

Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2015

At a glance

  • Drugs Adalimumab (Primary) ; Fumaric acid
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms CASTIP
  • Most Recent Events

    • 16 May 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 27 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top